333 related articles for article (PubMed ID: 26191237)
1. Immunohistochemical differentiation between type B3 thymomas and thymic squamous cell carcinomas.
Su XY; Wang WY; Li JN; Liao DY; Wu WL; Li GD
Int J Clin Exp Pathol; 2015; 8(5):5354-62. PubMed ID: 26191237
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
[TBL] [Abstract][Full Text] [Related]
3. CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma.
Angirekula M; Chang SY; Jenkins SM; Greipp PT; Sukov WR; Marks RS; Olivier KR; Cassivi SD; Roden AC
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565429
[TBL] [Abstract][Full Text] [Related]
4. CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma.
Kanamori K; Suina K; Shukuya T; Takahashi F; Hayashi T; Hara K; Saito T; Mitsuishi Y; Shimamura SS; Winardi W; Tajima K; Ko R; Mimori T; Asao T; Itoh M; Kawaji H; Suehara Y; Takamochi K; Suzuki K; Takahashi K
Thorac Cancer; 2023 Apr; 14(12):1089-1097. PubMed ID: 36924358
[TBL] [Abstract][Full Text] [Related]
5. Expression of proteasome subunit β5t in thymic epithelial tumors.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
[TBL] [Abstract][Full Text] [Related]
6. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
7. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
Thomas de Montpréville V; Quilhot P; Chalabreysse L; De Muret A; Hofman V; Lantuéjoul S; Parrens M; Payan MJ; Rouquette I; Secq V; Girard N; Besse B; Marx A; Molina TJ
Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
Hayashi A; Fumon T; Miki Y; Sato H; Yoshino T; Takahashi K
J Clin Exp Hematop; 2013; 53(1):9-19. PubMed ID: 23801129
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms.
Pomplun S; Wotherspoon AC; Shah G; Goldstraw P; Ladas G; Nicholson AG
Histopathology; 2002 Feb; 40(2):152-8. PubMed ID: 11952859
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
Du MJ; Shen Q; Yin H; Rao Q; Zhou MX
Pathol Res Pract; 2016 Nov; 212(11):1048-1051. PubMed ID: 27688088
[TBL] [Abstract][Full Text] [Related]
12. Tumour eosinophilia combined with an immunohistochemistry panel is useful in the differentiation of type B3 thymoma from thymic carcinoma.
Khoury T; Chandrasekhar R; Wilding G; Tan D; Cheney RT
Int J Exp Pathol; 2011 Apr; 92(2):87-96. PubMed ID: 21044186
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas.
Roden AC; Yi ES; Jenkins SM; Donovan JL; Cassivi SD; Garces YI; Marks RS; Aubry MC
Hum Pathol; 2015 Jan; 46(1):17-25. PubMed ID: 25455993
[TBL] [Abstract][Full Text] [Related]
14. Vascular architecture as a diagnostic marker for differentiation of World Health Organization thymoma subtypes and thymic carcinoma.
Pfister F; Hussain H; Belharazem D; Busch S; Simon-Keller K; Becker D; Pfister E; Rieker R; Ströbel P; Marx A
Histopathology; 2017 Apr; 70(5):693-703. PubMed ID: 27791295
[TBL] [Abstract][Full Text] [Related]
15. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
Kuo TT; Chan JK
Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
[TBL] [Abstract][Full Text] [Related]
16. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
Dorfman DM; Shahsafaei A; Chan JK
Am J Surg Pathol; 1997 Aug; 21(8):936-40. PubMed ID: 9255257
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
Nonaka D; Henley JD; Chiriboga L; Yee H
Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical panel consisting of EZH2, C-KIT, and CD205 is useful for distinguishing thymic squamous cell carcinoma from type B3 thymoma.
Kim BS; Kim JK; Kang CH; Kim YT; Jung KC; Won JK
Pathol Res Pract; 2018 Mar; 214(3):343-349. PubMed ID: 29487009
[TBL] [Abstract][Full Text] [Related]
19. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
20. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
